ESR2 and invasive breast carcinoma: Notably, Kaplan-Meier survival analysis revealed that high levels of ESR2 in patients with invasive breast carcinoma, demonstrate a significantly lower overall survival, as compared to breast tumors with low ESR2 expression (Figure 1D).